HK Stock Market Move | QINGSONG HEALTH (02661) rose more than 14% to a record high. Since its listing, the stock price has increased by 40%. Recently, the evidence-based medical intelligent body "Zheng Yuanfang" was released.

QINGSONG HEALTH (02661) rose more than 14% in midday trading, reaching a high of 125.9 Hong Kong dollars, setting a new record high since its listing on March 9, with a cumulative increase of more than 40%. As of the time of writing, it has risen by 12.28% to 123.4 Hong Kong dollars, with a trading volume of 96.9536 million Hong Kong dollars. On the news front, on March 9, QINGSONG HEALTH officially released its evidence-based medical intelligent system "Zheng Yuanfang". This product is designed based on the evidence-based medical methodology as the core design logic, targeting real clinical scenarios, and providing doctors with interpretable, verifiable, and traceable medical decision support. While filling the gap in the domestic evidence-based medical AI product market, it has also completed the fundamental transformation of medical AI from "medical question and answer tool" to "evidence-based decision assistant", evolving into a core product with greater commercial potential. It is reported that in the CMB 2023 China Practicing Physician Qualification Examination baseline test, Zheng Yuanfang scored a perfect score with a 100% accuracy rate, becoming the first AI system in China to score full marks in a national-level medical examination. In the more difficult high-level examinations in oncology, Zheng Yuanfang achieved State of the Art (SOTA) results in advanced problems such as complex disease judgment, weighing multiple treatment options, and evidence-based reasoning, performing significantly better overall than many domestic and foreign similar products, including Open Evidence.